Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M02D1 in triple negative breast cancer and solid tumors
NCT05339685Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M02D1 in triple-negative breast cancer (TNBC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
BL-M02D1
03
Conditions
triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT05339685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339685.